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INTRODUCTION
Hyaluronan is a major polysaccharide component of the extracellular matrix and is distributed widely
throughout the human body in connective, neural and epithelial tissue. The hyaluronan polymer
consists of disaccharide monomer units, D-glucuronic acid and D-N-acetyl glucosamine, and can range
in size from 5000 Da to in the order of 1 million Da (Cyphert et al. 2015). A dynamic balance between
the length of hyaluronan molecules within the extracellular matrix and their binding to cell surface
receptors such as CD44 (Zöller 2015) is believed to play a significant role in cell signalling responses
to events such as tumour invasion and inflammation. As a non-immunogenic, biocompatible and non-
toxic compound, hyaluronan has also been studied extensively in the last decade as an agent for
improved drug delivery (Tripodo et al. 2015).
The ability to efficiently introduce DNA of choice into mammalian cells has become more important
than ever due to the emergence of powerful genome-editing tools, such as those based on the
BIOLOGICAL SCIENCES

Hyaluronan treatment of biotinylated packaging cells
increases titre of progeny retrovirus affinity-captured
onto paramagnetic particles.
DARREN N. NESBETH 
1.  Department of Biochemical Engineering, University College London, Bernard Katz Building, London, United Kingdom WC1E 6BT
ABSTRACT
BACKGROUND: The polysaccharide hyaluronan is a major component of the extracellular matrix and has been observed to impact
retrovirus infectivity in biological settings. Hyaluronan has also been applied in biotechnology as a non-immunogenic, biocompatible
agent to improve control of drug delivery and lentiviral transduction. We carried out a preliminary investigation to ascertain if the
presence of hyaluronan influenced titre performance of an engineered retrovirus during the production, capture and infection steps
that constitute key metrics for retroviral bioprocess performance.
RESULTS: The PG13.pBabe.puro stable packaging cell line constitutively produces retroviral particles with the gibbon ape
leukaemia virus (GaLv) envelope protein and was used here with HeLa cells for retrovirus titration. An established bench-scale
retrovirus production procedure was investigated in which packaging cells are chemically biotinylated and progeny retrovirus bound
to streptavidin-coated paramagnetic particles (SPMPs) to achieve both retrovirus concentration and enhanced retroviral infection of
target cells. Post-biotinylation incubation of PG13.pBabe.puro cells with up to 100µg/mL hyaluronan did not impact the base titre of
unconcentrated progeny retrovirus. Incubation of target HeLa cells with up to 100µg/mL hyaluronan did not influence the
susceptibility of HeLa cells to infection by retrovirus bound to SPMPs. However, post-biotinylation incubation of PG13.pBabe.puro
cells increased titre of progeny retrovirus bound to SPMPs by up to 395%.
CONCLUSION: These observations are consistent with the hypothesis that the presence of haluronan after packaging cell
biotinylation increases the efficiency of capture of biotinylated retrovirus by SPMPs. Further work will be needed to confirm if this is
indeed the case and if packaging cell incubation with hyaluronan, or related biocompatible carbohydrates, could improve bioprocess
performance of other retro- or lenti- viral vectors in therapeutic applications.
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bacterial clustered regularly interspaced short palindromic repeats (CRISPR) / Cas9 nuclease system
(Sachdeva et al. 2015), and potent immunotherapeutic strategies, such as engineered T cells (Qasim
et al. 2015). These advances present a clear ongoing incentive for boosting the effectiveness of
retroviral and lentiviral transduction. We suggest that any and all routes to increasing the efficiency of
harvesting retroviral particles and maximising subsequent infectivity of captured virus should be
reported where possible in order to develop a diversity of tools and avenues of investigation.
In biological settings the presence of hyaluronan has largely been shown to inhibit or block retro- or
lenti-viral infection (Turville 2014). Efforts to deliver lentivirus in vivo to tissues have as result been
helped by the use of hyaluronan breakdown enzymes such as hyaluronidase (Wanisch et al. 2013).
However, in other therapeutic contexts, complexing viral vectors within polysaccharide scaffold mimics
of the extracellular matrix has proven advantageous for transduction of target cells (Thomas and Shea
2013, Sun et al. 2014)
Le Doux et al. (1999) previously reported that hyaluronan inhibits retroviral transduction. However,
Hughes et al. (2001) showed that paramagnetic particles coated with antibodies to the extracellular
matrix component, fibronectin, could capture retrovirus particles secreted from the fibroblast-derived
packaging cell line, PG13.pBabe.puro (Miller et al. 1991). Fibronectin and hyaluronan are believed to
interact extensively to define extracellular matrix behaviour in normal and cancerous tissues (Evanko
et al. 2015). Hughes et al. (2001) also reported that paramagnetic particles coated with the lectin
Concanavalin A, which is known to bind the carbohydrate component of cell surface glycoproteins
(Pratt et al. 2012), could efficiently capture retroviral particles. However, chemical biotinylation of
PG13.pBabe.puro cells allowed capture of progeny virus particles by streptavidin-coated paramagnetic
particles (SPMPs) and resulted in the highest retroviral titre increase in the Hughes et al. (2001) study.
In light of observations by Hughes et al. (2001), that the extracellular matrix components of packaging
cell appear to co-associate with their progeny retroviruses, we sought to test the hypothesis that the
presence of an additional, exogenous extracellular matrix component, hyaluronan, could enhance the
capture of biotinylated progeny virus from PG13.pBabe.puro cells. Possible mechanisms for such an
enhancement of capture include cross-linking of streptavidin-bound virus particles to non-bound
particles via hyaluronan-based interactions.
 
MATERIALS AND METHODS
Hyaluronan preparation. Hyaluronic acid sodium salt from rooster comb (product code H5388,
Sigma-Aldrich, Munich, Germany) of MW = 1.3 million Da was dissolved to 5mg/mL in a hyaluronan
storage buffer (100mM sodium acetate, 100mM sodium chloride). Purified hyaluronidase enzyme
(provenance not recorded) was dissolved in hyaluronidase storage buffer (20mM sodium phosphate,
0.45 % w/v sodium chloride, 0.01 % w/v bovine serum albumen) to a concentration of 2mg / mL = 10 U
/ µL. 30µL of this hyaluronidase solution was mixed with 1.2mL of 5mg/mL hyaluronan and incubated
at 37°C over night in anticipation of achieving partial cleavage of hyaluronan into a mixture of different
molecular weight polysaccharides. Digested hyaluronan was then stored at 4°C and used for all
subsequent experimentation.
Standard virus production, capture and titration. The procedure reported by Hughes et al. (2001)
was followed as summarised in Figure 1. Briefly, on Day 1 of a given experiment 1x106
PG13.pBabe.puro cells were seeded onto a 9cm diameter round plate in 15mL Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 100
µg/mL streptomycin, and 100 U/mL penicillin. 5-8 plates were routinely seeded in order that 4 plates
with matching cell densities could be selected for further experimentation. Typically by Day 5 the
PG13.pBabe.puro cells reached 80-90% confluence, approximately 1-2x107 cells per 9cm plate. At this
stage growth media was removed and replaced with 10mL of pH 8.1 phosphate buffered saline (PBS)
solution containing 0.5mM biotin amido caproate N-hydroxy succinimide ester (BSE) from Sigma-
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Aldrich (product code B2643) and 0.75mM of CaCl2 and MgCl2. Cells were incubated at room
temperature for 30 min, then the BSE solution removed and replaced with growth medium and the cells
returned to 37°C. After 2 hours at 37°C that medium was discarded and replaced again with fresh
medium for overnight (16 hours) incubation. Also on Day 5 HeLa cells were plated in wells of a 24 well
plate at 5x104 cells per well.
At the start of Day 6 of the procedure polybrene was added to HeLa cell growth medium to a final
concentration of 4.4µg / mL 4 hours prior to their infection with retrovirus. 1.25 x109 SPMPs in 2.5mL
PBS was then transferred to a 15mL Falcon tube and a Dynal® MPC-6 magnetic particle concentrator
(Invitrogen, Carlsbad, California, USA) used to remove liquid from beads, as described by Hughes et
al. (2001), leaving only a bead pellet. Over night growth medium from PG13.pBabe.puro cells was
removed from cells, passed through a 45µM filter and 5mL added to the SPMP pellet. This SPMP
slurry was then placed on a roller for 90 mins at 4°C for virus capture. An MPC was then used to
reduce the volume of the bead slurry to 20µL. Aliquots of this concentrated virus:SPMP suspension
were serially diluted for titration purposes and a volume of 100µL always used to infect HeLa cells.
HeLa cells were subjected to puromycin selection at 5µg / mL on Day 8 and monitored for cell death
and emergence of resistant colonies over Days 9-20. Puromycin-resistant cell colonies were stained
with Coomassie, as described by Hughes et al. (2001), and counted.
Hyaluronan treatment of target cells. At the stage in the above procedure where polybrene is added
to HeLa target cells, digested hyaluronan was also added to some HeLa cell wells, to a final
concentration of 1µg/mL, 10µg/mL or 100µg/mL and always to give a final growth medium volume of
1mL.
Hyaluronan treatment of packaging cells. Hyaluronan was added, to the indicated final
concentrations, to the fresh medium used for overnight (16 hour) incubation of PG13.pBabe.puro cells
at the end of Day 5.
RESULTS AND DISCUSSION
Previous work by Hughes et al. (2001) demonstrated that infectious retroviral particles are secreted
continuously from the stable packaging cell line PG13.pBabe.puro into the surrounding growth media.
Hughes et al. (2001) also reported that biotinylation of PG13.pBabe.puro cells by chemical means
enabled capture of progeny retrovirus by SPMPs. SPMP binding enabled concentration of retroviral
particles and a concomitant increase in infectivity likely due to enforced settling of virus particles onto
target cells by the action of gravity or directed electromagnetic attraction.
We repeated the procedures reported by Hughes et al. (2001) for cultivation and chemical biotinylation
of PG13.pBabe.puro packaging cells, SPMP-based capture of progeny retrovirus and infection of HeLa
cells for retroviral titration (Figure 1). We also modified these procedures by either incubating
PG13.pBabe.puro packaging cells with hyaluronan after their biotinylation (Figures 2 and 4) or by
incubating the target HeLa cells with hyaluronan prior to their infection (Figure 3).
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Figure 1: Capture and concentration of biotinylated retrovirus by straptavidin-coated paramagnetic
particles (SPMPs) and titration by infection of HeLa cells. Summary of procedure detailed in Materials
and Methods. The PG13.pBabe.puro cell line (Pack. Cells) constitutively produces retroviral particles
and was plated on Day 1. On Day 5 HeLa cells (Target Cells) were plated for titration and
PG13.pBabe.puro growth medium was replaced with a biotinylation solution (dark medium) that was
then replaced with fresh medium (light medium) overnight. On Day 6 HeLa cells were incubated with
polybrene 4 hours prior to infection with unconcentrated, virus-containing supernatant from
PG13.pBabe.puro cells (uppermost dark arrow). Also on Day 6 SPMPs (pentagons) were concentrated
by complete liquid removal then resuspension (open arrow) in virus-containing supernatant. Virus-
bound SPMPs were then concentrated and used to infect HeLa cells for titration (lowermost dark
arrow). H indicates steps in which a hyaluronan incubation was added as detailed in Materials and
Methods.
 
Post-biotinylation hyaluronan treatment of PG13.pBabe.puro cells did not influence infectivity
of progeny retroviral particles in solution. After the biotinylation of PG13.pBabe.puro packaging
cells we incubated the cells with hyaluronan at the concentrations indicated in Figure 2, for 16 hours
(see also the uppermost ‘H’ in Figure 1). We then removed and retained the PG13.pBabe.puro cell
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growth medium and used it to infect HeLa cells for titration of infectious viruses following the procedure
of Hughes et al. (2001). We anticipated that using such a relatively low titre, unconcentrated retrovirus
solution would best reveal any increase in retrovirus infectivity or production resulting from the
incubation with hyaluronan.
The presence of hyaluronan during post-biotinylation incubation of PG13.pBabe.puro cells had no
influence on the infectivity of progeny virus particles (Figure 2). This suggest that hyaluronan, unlike
agents such as sodium butyrate and caffeine (Ellis et al. 2011), does not act to stimulate additional
virus productivity of packaging cells. This result is also consistent with the hypothesis that any
hyaluronan that may remain associated with progeny virus particles after their release from packaging
cells does not act to increase the frequency of subsequent infection events.
 
Figure 2: Titre of free retrovirus produced from biotinylated packaging cells incubated with hyaluronan.
After chemical biotinylation PG13.pBabe.puro packaging cells were incubated with 0µg/mL, 1µg/mL,
10µg/mL or 100µg/mL hyaluronan (as indicated in axis labels) for 16 hours. 100µL of this
PG13.pBabe.puro packaging cell medium was then added to target HeLa cells and resultant
puromycin-resistant colony numbers counted. Error bars indicate standard deviation over n=3
biological repeats.
Incubating HeLa cells with hyaluronan did not enhance their susceptibility to infection by
retroviral particles bound to SPMPs. We next sought to determine directly if hyaluronan treatment of
target cells can increase the frequency of infection events achieved by a given amount of retroviral
material. To do this we tested whether a 4-hour incubation of HeLa cells with hyaluronan influenced
their infection by SPMP-bound retroviral particles derived from PG13.pBabe.puro cells. Figure 3
indicates that incubating HeLa cells with up to 100 µg / mL hyaluronan had no effect on their infection
by SPMP-bound retrovirus.
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Figure 3: Titre of SPMP-bound retrovirus used to infect HeLa cells pre-incubated with hyaluronan.
HeLa cells were seeded in 24 well plate as targets for retroviral infection (as in Figures 2 and 4) and 24
hours later growth medium was supplemented either with additional growth medium (indicated by
‘0µg/mL’ in x axis labels), polybrene to 4µg/mL (indicated by ‘PB’ in x axis labels), hyaluronan (to
1µg/mL, 10µg/mL or 100µg/mL, as indicated in axis labels) or with both polybrene and hyaluronan.
Cells were then incubated for 4 hours before a 100µL slurry of biotinylated retrovirus bound to SPMPs
was added for retrovirus titration. Error bars indicate standard deviation over n=3 biological repeats.
Post-biotinylation hyaluronan treatment of PG13.pBabe.puro cells enhanced SPMP-based
capture of progeny retrovirus. The previous data are consistent with the hypothesis that hyaluronan
does not stimulate either retrovirus production by packaging cells (Figure 2) or infection of target cells
by SPMP-bound retrovirus (Figure 3). As such we finally asked the question, could hyaluronan
influence the biophysical process of retrovirus capture by SPMPs? To answer this question we
incubated PG13.pBabe.puro packaging cells as previously for 16 hours with up to 100 µg / mL
hyaluronan after their chemical biotinylation. However this growth medium was now incubated with
SPMPs for virus capture and concentration. Figure 4 shows that this hyaluronan treatment increased
the average titre of subsequently SPMP-bound retrovirus 395% in the case of 100 µg / mL hyaluronan.
The data in Figure 4 are consistent with hyaluronan acting to favour increased capture of biotinylated
retrovirus by SPMPs. However these data do not rule out other possibilities, for instance that
hyaluronan could be utilised as a nutrient by PG13.pBabe.puro cells to effect an increase in cell growth
and/or virus production. However, it is worth considering that chemical biotinylation of
PG13.pBabe.puro cells is terminated by both removal of the BSE reagent and a 2-hour incubation with
ultimately discarded growth medium prior to addition of hyaluronan in fresh medium. As such any
significant post-biotinylation increase in cell or virus numbers compared to non-hyaluronan treated
cells would also likely dilute the level of biotinylation of the additional cells and virus particles. Another
possibility is that any residual hyaluronan associated with virus-bound SPMPs (Figure 4) may favour
HeLa cell infection events in a manner that does not manifest itself when free virus particles infect
HeLa cells in the presence of hyaluronan (Figure 2).
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Figure 4: Titre of SPMP-bound retrovirus produced from biotinylated packaging cells incubated with
hyaluronan. After chemical biotinylation, PG13.pBabe.puro packaging cells were incubated with
hyaluronan for 16 hours as described in Figure 2. These packaging cell growth media with different
hyaluronan concentrations were each then mixed with SPMPs and the resultant virus-bound SPMPs
concentrated using an MPC. The bead slurry was then titrated using HeLa target cells. Error bars
indicate standard deviation over n=3 biological repeats.
CONCLUSIONS
In conclusion, we have shown that post-biotinylation incubation of a retroviral packaging cell with
hyaluronan increased the titre of subsequently paramagnetic particle-bound virus by up to 395%. We
suggest this increased titre was due to enhanced virus capture. The success of this preliminary study
indicates that further investigation is warranted into addition of exogenous agents to enhance lenti- or
retrovirus production and capture.
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